Riverbridge Partners LLC trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 7.0% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 481,126 shares of the company's stock after selling 36,407 shares during the quarter. Medpace comprises about 2.4% of Riverbridge Partners LLC's portfolio, making the stock its 8th biggest holding. Riverbridge Partners LLC owned approximately 1.59% of Medpace worth $146,594,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently modified their holdings of MEDP. Blue Trust Inc. increased its stake in shares of Medpace by 60.5% in the first quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $142,000 after buying an additional 176 shares during the period. QRG Capital Management Inc. boosted its position in Medpace by 10.9% in the first quarter. QRG Capital Management Inc. now owns 13,050 shares of the company's stock worth $3,976,000 after purchasing an additional 1,283 shares during the last quarter. Asio Capital LLC bought a new stake in shares of Medpace in the first quarter valued at $2,213,000. Vista Finance LLC raised its stake in shares of Medpace by 6.9% in the first quarter. Vista Finance LLC now owns 1,113 shares of the company's stock valued at $339,000 after buying an additional 72 shares during the period. Finally, Marshall Financial Group LLC raised its stake in shares of Medpace by 13.7% during the 1st quarter. Marshall Financial Group LLC now owns 2,935 shares of the company's stock valued at $894,000 after purchasing an additional 354 shares during the period. 77.98% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the transaction, the director now directly owns 2,998 shares of the company's stock, valued at $904,856.36. This trade represents a 36.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.30% of the stock is currently owned by insiders.
Medpace Price Performance
MEDP stock traded down $0.72 during trading on Monday, hitting $308.64. The stock had a trading volume of 566,600 shares, compared to its average volume of 369,155. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $459.77. The stock has a market capitalization of $8.87 billion, a P/E ratio of 23.56, a PEG ratio of 5.58 and a beta of 1.47. The company's 50-day moving average price is $299.94 and its two-hundred day moving average price is $320.87.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.06 by $0.61. Medpace had a return on equity of 54.36% and a net margin of 19.31%. The company had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. During the same period in the previous year, the firm posted $3.20 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms recently commented on MEDP. Truist Financial reduced their target price on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research report on Wednesday, April 23rd. Leerink Partnrs raised Medpace to a "hold" rating in a research report on Monday, March 24th. Leerink Partners initiated coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective for the company. Robert W. Baird reduced their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Finally, William Blair reaffirmed a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $349.30.
View Our Latest Stock Report on Medpace
About Medpace
(
Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Read More
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
